(Q36909303)

English

Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects

scientific article published on August 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

Europe PubMed Central

Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Andreas Pfützner

1

object named as

Andreas Pfützner

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

author name string

Matthias M Weber

2

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Thomas Forst

3

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

language of work or name

0 references

publication date

1 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1985-1998

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Pancreatic beta-cell loss and preservation in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Trends in the leading causes of death in the United States, 1970-2002.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Rosiglitazone/Metformin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Thiazolidinediones: an update.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

The pleiotropic functions of peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

PPARgamma, the ultimate thrifty gene

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Inflammatory biomarkers in stable atherosclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Platelet inhibition by insulin is absent in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Cardiovascular effects of rosiglitazone

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Bone is a target for the antidiabetic compound rosiglitazone.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Insulin resistance and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioglitazone: a review of its use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

The DREAM trial – Authors' reply

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.12.1985

21 January 2018

Identifiers

10.1517/14656566.8.12.1985

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36909303&oldid=2088563677"